Sphingosine kinase 1 (SK1) catalyses the formation of bioactive phospholipid sphingosine 1-phosphate (S1P). Elevated cellular SK1 activity and S1P levels enhance cell proliferation and survival, and are strongly implicated in tumourigenesis. Regulation of SK1 activity can occur through various mechanisms, including phosphorylation and protein-protein interactions. We have previously shown that eukaryotic elongation factor 1A (eEF1A) interacts with and directly activates SK1, but the mechanisms regulating this were undefined. Notably, eEF1A has GTPase activity and can exist in GTP-or GDP-bound forms, which are associated with distinct structural conformations of the protein. Here, we show that the guanine nucleotide-bound state of eEF1A regulates its ability to activate SK1, with eEF1A.GDP, but not eEF1A.GTP, enhancing SK1 activity in vitro. Furthermore, we show that enhancing cellular eEF1A. GDP levels through expression of a guanine nucleotide dissociation inhibitor of eEF1A, translationally controlled tumour protein (TCTP), increased SK1 activity in cells. We also examined a truncated isoform of eEF1A1, termed prostate tumour inducer-1 (PTI-1), which can induce neoplastic cell transformation through undefined mechanisms. PTI-1 lacks the G protein domain of eEF1A1 and is therefore unable to undergo the GTP-binding-induced conformational change. Notably, we found that PTI-1 can directly activate SK1 and that this seems to be essential for neoplastic transformation induced by PTI-1, as chemical SK1 inhibitors or overexpression of a dominant-negative SK1 blocked this process. Thus, this study defines the mechanism regulating eEF1A-mediated SK1 activation, and also establishes SK1 as being integral for PTI-1-induced oncogenesis.
Introduction
Sphingosine kinase 1 (SK1) catalyses the generation of sphingosine 1-phosphate (S1P), a bio-active phospholipid involved in controlling many biological processes, including calcium mobilization, cell proliferation, apoptosis and cytoskeleton rearrangement (Hait et al., 2006) . SK1 has a crucial role in determining the cellular balance of pro-apoptotic ceramide and sphingosine and pro-proliferative, pro-survival S1P, and there is now substantial evidence that SK1 has a role in tumourigenesis (Cuvillier, 2008) . For example, SK1 expression is elevated in a variety of human solid tumours (French et al., 2003) , overexpression of SK1 in NIH 3T3 fibroblasts leads to their neoplastic transformation , chemical inhibition or genetic ablation of SK1 reduces tumour growth in vivo (French et al., 2003; Kohno et al., 2006; Kawamori et al., 2009) and SK inhibitors or a dominant-negative SK1 can reduce neoplastic cell transformation induced by oncogenic H-Ras .
Activation of SK1 seems to be important for the oncogenic signalling by this enzyme (Pitson et al., 2005) . Various mechanisms of SK1 activation have been reported, including phosphorylation (Pitson et al., 2003) and various protein-protein interactions (reviewed in Taha et al., 2006) . We recently reported that eukaryotic elongation factor 1A1 and -2 (eEF1A1 and eEF1A2) are closely related proteins that can associate with and directly increase the catalytic activity of SK1 both in vitro and in cells (Leclercq et al., 2008) . eEF1A proteins have canonical roles in protein synthesis, transporting aminoacyl transfer RNAs to the ribosome during polypeptide elongation (Abbott and Proud, 2004) . Many other 'moonlighting' roles for eEF1A have, however, been described, including cytoskeletal remodelling, enzyme regulation and apoptosis (Ejiri, 2002) . Furthermore, substantial evidence now exists that deregulation of eEF1A can lead to cancer (Al-Maghrebi et al., 2005) , although the molecular mechanisms whereby this occurs remain undefined. Our previous findings that eEF1A proteins can activate SK1 raised the possibility that SK1 may mediate the oncogenic effects associated with deregulated eEF1A.
Here we show that the guanine nucleotide bound state of eEF1A regulates its ability to activate SK1.
Furthermore, we demonstrate that SK1 is integral for neoplastic transformation induced by a truncated, oncogenic form of eEF1A termed prostate tumour inducer-1 (PTI-1), which is defective in nucleotide binding.
Results and Discussion
As eEF1A1 is a highly abundant cellular protein, we have previously hypothesized that its association with protein targets is likely to be regulated to provide specificity in its functions (Leclercq et al., 2008) . Indeed, association of eEF1A1 with a number of its protein targets seems to be regulated by phosphorylation, either of eEF1A1 or its partners (Ejiri, 2002) . This does not seem to be the case, however, for the eEF1A1-SK1 interaction, in which phosphorylation does not seem to have a role (Leclercq et al., 2008) . Thus, the mechanisms regulating this interaction and the subsequent activation of SK1 by eEF1A have remained undefined.
eEF1A has GTPase activity, and its G protein domain is known to function in its role in protein synthesis. Thus, eEF1A is believed to exist in cells in two structurally distinct conformational states that are brought about through its association with either GTP or GDP (Andersen et al., 2003) . Structural analysis of the bacterial homologue of eEF1A, EF1A (previously termed EF-Tu), which is structurally similar to eEF1A (Andersen et al., 2000) , has revealed that nucleotide-free and GDP-bound EF1A seem to have a somewhat similar conformation that is markedly different to that of the GTP-bound protein, especially in the two C-terminal domains (Andersen et al., 2003) . This raised the possibility that the guanine nucleotide-bound state of eEF1A may regulate its effect on SK1. To investigate this, we loaded purified recombinant eEF1A1 with either GDP or non-hydrolysable GTPgS, and then examined their effect on the activity of purified recombinant SK1 in vitro (Figure 1 ). Similar to untreated eEF1A (Leclercq et al., 2008) , GDP-bound eEF1A1 was able to activate SK1. Remarkably, however, eEF1A1 treated with GTPgS completely lost its ability to enhance SK1 activity.
Having established that it is selectively the GDPbound form of eEF1A1 that activates SK1 in vitro, we next examined whether this mode of regulation also functions to control SK1 activity in cells. To do this, we used translationally controlled tumour protein (TCTP), which has been described as a guanine nucleotide dissociation inhibitor for eEF1A, stabilizing the protein in its GDP-bound form (Cans et al., 2003) . Initially, we confirmed the ability of TCTP to stabilize eEF1A in a GDP-bound state, by showing that TCTP overexpression markedly increased the amount of GDP associated with eEF1A1 ( Figure 2a ). Subsequent examination of the effect of this on SK1 activity showed that, consistent with our in vitro findings, overexpression of TCTP in quiescent Chinese hamster ovarian (CHO) cells resulted in an increase in endogenous SK1 activity (Figure 2b ), which was comparable to that previously seen with eEF1A overexpression (Leclercq et al., 2008) . Notably, this increase in cellular SK1 activity was even greater when TCTP and eEF1A1 were both overexpressed in this system (Figure 2b) . Similarly, overexpression of TCTP alone in proliferating cells also enhanced SK1 activity to a comparable extent to that seen in quiescent cells, as measured by both direct measurement of SK1 activity in cell lysates ( Figure 3a ) and S1P formation in intact cells (Figure 3b ). These results, along with our Figure 1 Guanine nucleotides regulate the effect of eEF1A on SK1 activity. Purified recombinant eEF1A1 was combined with 1 mM GDP or GTPgS in 25mM Tris-HCl buffer (pH 7.4) containing 10% glycerol, 75 mM NaCl, 1 mM Na 3 VO 4 , 5 mM NaF, 5 mM b-glycerophosphate, 0.5 mM EDTA and 0.025% Triton X-100 (Buffer A) or Buffer A alone (eEF1A1), and then added at 10-fold molar excess to purified recombinant SK1 (Pitson et al., 2002) . Efficient binding of GDP and GTP to recombinant eEF1A1 was confirmed using 3 H-labelled GDP and GTP (GE Healthcare, Sydney, Australia), which showed percentage molar incorporation of GDP and GTP to eEF1A1 of 80 ± 13 and 98 ± 20%, respectively (mean ± s.e.m. of triplicate determinations). Samples were immediately analysed in an in vitro SK1 activity assay using D-erythro-sphingosine and [g-32 P]ATP as substrates (Roberts et al., 2004) . Data are mean ±s.e.m. for four independent experiments. *Po0.05, **Po0.001 compared with the activity of SK1 alone (control). Generation of the expression construct for eEF1A1 with an N-terminal T7 tag and a C-terminal TEV-cleavable 6xHis tag (T7-eEF1A1/TEV/His) was performed by PCR amplification from pGEX4T1-eEF1A1 (HA) (Leclercq et al., 2008) using the following oligonucleotides: 5 0 -TAGGATCCAATGGGAAAGGAAAAGACTCATA-3 0 and 5 0 -TAG-AATTCAGTGATGGTGATGGTGATGTTCCAGGCC CTGAAAATACAGGTTTTCTTTAGCCTTCTGAGCTTTCTG-3 0 . The product was then digested with BamHI and EcoRI and cloned into pET17b (Merck, Darmstadt, Germany). T7-eEF1A1/TEV/His protein was expressed in E. coli BL21 DE3 essentially as described previously (Leclercq et al., 2008) , except that protein expression was induced with 0.4 mM isopropyl b-D-thiogalactopyranoside for 60 min. To purify the T7-eEF1A1/TEV/His protein, clarified bacterial lysate (50 mM Tris-HCl (pH 7.4) containing 150 mM NaCl, 10% glycerol and 20 mM imidazole) was incubated with Ni-sepharose (Invitrogen, Melbourne, Australia) and mixed at 4 1C for 3 h. The resin was then washed three times in cold phosphatebuffered saline, T7-eEF1A1/TEV/His eluted into 50 mM Tris-HCl (pH7.4) containing 150 mM NaCl, 10% glycerol and 500 mM imidazole, desalted into Buffer A and then cleaved with TEV protease (Invitrogen) according to the manufacturer's protocol. Cleaved T7-eEF1A1 was then incubated with Ni-sepharose to remove the 6xHis peptide and His-tagged TEV protease.
SK1 mediates eEF1A-associated oncogenesis TM Leclercq et al in vitro data, suggest that, in cells, eEF1A1.GDP is responsible for the increase in SK1 activity attributed to eEF1A1. To further examine this, we used T47D breast cancer cells in which, in contrast to CHO cells, TCTP levels were detectable (Tuynder et al., 2002) . Small interfering RNA knockdown of TCTP in these cells resulted in a significant decrease in endogenous SK1 activity, whereas SK1 protein levels were unaltered (Figure 2c ). This is, again, consistent with our findings that regulation of the guanine nucleotide-bound state of eEF1A can control the activity of SK1 in cells.
Two isoforms of eEF1A exist, eEF1A1 and eEF1A2, which arise from different genes but possess 92% polypeptide sequence identity. Although eEF1A1 is ubiquitous, eEF1A2 expression is normally restricted to heart, brain and skeletal muscle cells (Thornton et al., 2003) , but has been detected in malignant cells from other tissues, in which it has been implicated in inducing the neoplastic phenotype through undetermined means (Lee, 2003) . Similar to eEF1A1, eEF1A2 associates with and activates SK1 (Leclercq et al., 2008) . Furthermore, small interfering RNA-mediated knockdown of eEF1A2 in MCF-7 breast cancer cells, in which eEF1A2 is the major eEF1A isoform expressed, also caused a decrease in cellular SK1 activity, suggesting a role for both eEF1A1 and -2 in SK1 regulation (Leclercq et al., 2008) . Levels of eEF1A1 in proliferating CHO cells are high and its further overexpression does not alter endogenous SK1 activity (Leclercq et al., 2008) . Remarkably, however, we found that ectopic overexpression of eEF1A2 in proliferating CHO cells, in which this isoform is not normally expressed, resulted in an Figure 2 TCTP expression increases GDP-associated eEF1A and enhances cellular SK1 activity. (a) Proliferating CHO-K1 cells were transiently transfected, as previously described (Leclercq et al., 2008) , with pcDNA3 (vector), or vectors encoding for haemagglutinin (HA)-tagged eEF1A1 and HA-tagged TCTP. Levels of GDP associated with eEF1A were determined through 32 P i incorporation as previously described (Satoh et al., 1990) . Briefly, 1 day after transfection, cells were placed into phosphate-free medium for 30 min at 37 1C and 5% CO 2 , then incubated with 300 mCi [ 32 P]orthophosphate (Perkin-Elmer, Melbourne, Australia) for a further 4 h under the same conditions. Cells were then harvested by scraping into cold phosphate-buffered saline and lysed by three passes through a 26-gauge needle in extraction buffer A containing 1 mM dithiothreitol (DTT) and protease inhibitors (Complete; Roche Applied Science, Sydney, Australia). Lysates were clarified by centrifugation at 13 000 g for 15 min at 4 1C. Overexpressed eEF1A1 was immunoprecipitated with anti-HA antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 3 h at 4 1C with constant mixing. The immune complexes were captured by incubation with protein A-Sepharose (GE Healthcare) for 3 h at 4 1C with constant mixing, followed by washes with cold buffer A. Immuno-precipitated eEF1A1 was released from the protein A-Sepharose by resuspension in 5 mM Tris-HCl buffer (pH 7.4) containing 2 mM DTT and 2 mM EDTA, and boiling for 5 min. The eluant was cooled on ice for 10 min and then subjected to SDS-PAGE analysis to confirm protein expression and immunoprecipitation, and also thin-layer chromatography (TLC) to quantitate GDP levels. Cellulose fibre TLC plates (Sigma Aldrich, St Louis, MO, USA) were developed with 0.5 M KH 2 PO 4 , pH 3.4, and the [ 32 P]GDP associated with eEF1A1 visualized by phosphorimager (GE Healthcare) and compared with eEF1A1 alone. Data are representative of two independent experiments. Dotted lines indicate where lanes from the same immunoblot or TLC plate have been spliced together to simplify viewing. The TCTP expression construct was produced by PCR amplification from human placenta cDNA using the following primers: 5 0 -TAGAATTCCTATGATTATCTACCGGGACCTC-3 0 and 5 0 -TAGAATTCTTAACATTTTTCCATTTTTAAACCA-3 0 . The PCR product was digested with EcoRI and cloned into the pCMV(HA) vector (Clontech, Mountain View, CA, USA) for mammalian expression with an N-terminal HA tag. (b) Lysates from quiescent CHO cells transiently expressing HA-tagged eEF1A1 or TCTP for 24 h were prepared and examined for endogenous SK1 activity as described previously (Figure 1 ). Data are mean ± s.e.m. from more than seven independent experiments. *Po0.01, **Po0.001, ***Po0.0001 compared with vector control. (c) T47D breast cancer cells were transfected with TCTP siRNA (5 0 -CAU GAACCAUCACCUGCAGGAAACA-3 0 ) or control siRNA (Invitrogen) duplexes using Lipofectamine RNAiMAX reagent (Invitrogen). Lysates were prepared 48 h later and analysed for endogenous SK1 activity as described previously (Figure 1) . TCTP, SK1 and a-tubulin (loading control) protein levels were examined by immunoblot with anti-TCTP (Medical & Biological Laboratories, Nagoya, Japan), anti-SK1 (Pitson et al., 2003) and anti-a-tubulin (Abcam, Cambridge, MA, USA) antibodies, respectively. Comparable results were obtained with another TCTP siRNA (5 0 -AUCUCCCGGAUCUUGUAGAUGUCGG-3 0 ). Data are mean ± s.e.m. for three independent experiments. *Po0.01 compared with control siRNA.
SK1 mediates eEF1A-associated oncogenesis TM Leclercq et al increase in cellular SK1 activity (Figures 3a and b) . Interestingly, ectopic expression of eEF1A2 in these proliferating CHO cells resulted in considerably more of this protein in the GDP-associated form than observed when eEF1A1 was overexpressed in the same cells (Figure 3c ). These findings are consistent with previous studies showing that, compared with eEF1A1, eEF1A2 has a higher preference for binding GDP than GTP in vitro (Kahns et al., 1998) , and that it has little or no affinity for the guanine exchange factor, eEF1B, which facilitates the exchange of GDP for GTP on eEF1A1 (Mansilla et al., 2002) . Together, these findings indicate that, similar to eEF1A1, the GDP-bound form of eEF1A2 seems to be responsible for the effect of this protein on SK1. A truncated form of eEF1A1, termed PTI-1, has been identified, which lacks the N-terminal 67 amino acids necessary for proper GTP/GDP binding (Gopalkrishnan et al., 1999) . As PTI-1 is unable to undergo the GTP-binding-induced conformation change proposed for intact eEF1A, we examined whether it may function as a constitutive activator of SK1. Furthermore, although the origin of PTI-1 has been the subject of some debate (Mansilla et al., 2005) , a number of studies have reported its expression specifically in tumour cells and tissues (Gopalkrishnan et al., 1999) , and demonstrated its ability to induce neoplastic transformation (Su et al., 1998) . The mechanism whereby PTI-1 exerts its oncogenic effects, however, has not been established. Thus, we examined the interaction of PTI-1 with SK1 and the potential for this association to have a role in PTI-1-induced oncogenesis.
Initially, the interaction between PTI-1 and SK1 was assessed by pull-down experiments using GST-PTI-1 and purified recombinant SK1. The results demonstrated a direct interaction of SK1 with PTI-1, which was comparable to its association with eEF1A1 ( Figure 4a ). We next investigated whether PTI-1 could directly activate SK1, and found that, similar to eEF1A1, addition of PTI-1 to purified recombinant SK1 enhanced the activity of this enzyme in vitro (Figure 4b) . Indeed, maximal effects of PTI-1 on SK1 activity were observed when the two proteins were present at equimolar concentrations, suggesting a specific and potentially physiologically relevant effect of this association. To determine this physiological significance of the SK1-PTI-1 interaction, PTI-1 was overexpressed in HEK293T cells and the level of endogenous SK1 activity in these cells was determined. The results show that unlike ectopic expression of eEF1A1 in these cells, which does not change cellular SK1 activity (Leclercq et al., 2008) , overexpression of PTI-1 resulted in an approximate 1.8-fold increase in SK1 activity in cell lysates and a similar increase in S1P formation in intact cells (Figure 4c ).
Ectoptic expression of PTI-1 or overexpression of SK1 have both been shown to induce neoplastic cell transformation (Su et al., 1998; Xia et al., 2000) . Thus, we next examined the possible role of SK1 in PTI-1-induced oncogenesis. Transformation of NIH3T3 cells ectopically expressing PTI-1 was assessed by focus formation assays in the presence of two different chemical inhibitors of SK1, N,N-dimethylsphingosine and 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole. SK1 mediates eEF1A-associated oncogenesis TM Leclercq et al Results (Figure 4d) show that, consistent with previous studies, PTI-1 expression in NIH3T3 cells caused the formation of large foci. Focus formation, however, was blocked by the presence of SK1 inhibitors, suggesting a role for SK1 activity in PTI-1-induced transformation. This effect was further confirmed by coexpression of a Figure 4 PTI-1 interacts with and activates SK1 to elicit neoplastic transformation. (a) Interaction of PTI-1 with SK1 was examined in vitro by incubating 1 mg of either glutathione-S-transferase (GST), GST-eEF1A1 (Leclercq et al., 2008) or GST-PTI-1 bound to glutathione-Sepharose with 1 mg of purified His-tagged recombinant SK1 in Buffer A for 3 h at 4 1C with constant mixing. The complexes were then isolated by pulse centrifugation at 4000 g, washed three times in 25 mM Tris-HCl, pH 7.4, containing 75 mM NaCl and 10% glycerol, and SK1 detected by immunoblotting with anti-His antibodies (Santa Cruz). (b) The effect of varying molar excess of purified GST-PTI-1 (filled circles) or GST control (open circles) on the catalytic activity of purified recombinant SK1 was determined by an in vitro SK1 activity assay. Data are mean±s.d. from three independent experiments. *Po0.05, **Po0.01 compared with GST. (c) HEK293T cells were transiently transfected with empty pcDNA3 vector (vector), or vectors encoding HA-tagged eEF1A1 or PTI-1. The cells were then analysed 24 h later by immunoblotting with anti-HA antibodies for expression of eEF1A1 and PTI-1 (upper panel), endogenous SK1 activity in cell lysates (middle panel) and S1P formation in intact cells (lower panel). Data are mean ± s.e.m. from three independent experiments. *Po0.05, **Po0.001 compared with vector. The PTI-1 expression constructs were produced by PCR amplification from pcDNA3-eEF1A1(HA) using the following primers: 5 0 -TAGAATTCGCCACCATGCAGTCAGTCGGAACGT GGTATCACCATTGAT-3 0 and SP6. The PCR product was digested with EcoRI and XhoI and then cloned into pcDNA3 for expression in mammalian cells with a C-terminal HA tag, or pGEX4T1 for expression in bacteria as a GST-fusion protein. (d) NIH3T3 fibroblasts were transiently transfected with vectors encoding PTI-1, a dominant-negative SK1 (SK1 DN ) or empty pcDNA3 vector (vector) and subjected to focus formation assays as previously described . SK inhibitors, SKi and DMS, were used at 5 and 2.5 mM, respectively and added every 2 days. After approximately 14 days, when foci were macroscopically visible, the medium was removed and cells washed, fixed and stained with methyl violet. Images are representative of three independent experiments. (e) NIH3T3 fibroblasts were transiently transfected with vectors encoding PTI-1 and SK1 DN and lysed 1 day later into Buffer A. FLAG-tagged SK1 DN was immunoprecipitated from these lysates by mixing with anti-FLAG antibodies and protein A-sepharose at 4 1C for 4 h. The levels of HA-tagged PTI-1 in the original lysates, SK1 DN immunoprecipitates and lysates after immunoprecipitation (post-IP lysates) were then determined by immunoblotting with anti-HA antibodies. Cells transiently transfected with vector encoding PTI-1 alone or empty pcDNA3 vector were used as controls. Dotted lines indicate where lanes from the same immunoblot have been spliced together to simplify viewing. SK1 mediates eEF1A-associated oncogenesis TM Leclercq et al dominant-negative form of SK1, which again blocked PTI-1-induced neoplastic transformation. Notably, under these conditions almost all of the PTI-1 was found to be bound by the dominant-negative SK1 (Figure 4e) , thereby reducing the availability of PTI-1 to interact with endogenous SK1. Taken together, these results suggest that the oncogenesis attributed to PTI-1 is mediated through the activation of SK1.
In conclusion, in this study, we have shown that the guanine nucleotide-bound state of eEF1A controls its effects on SK1, providing a molecular mechanism for regulation of eEF1A-mediated SK1 activation. Our studies also suggest that the reported oncogene PTI-1 can constitutively activate SK1 and that this is essential for PTI-1-induced oncogenesis. Intriguingly, we also found that other components in this pathway that have been implicated in oncogenesis, TCTP and eEF1A2, also have effects on cellular SK1 activity. Numerous studies have implicated elevated TCTP expression in oncogenesis, with targeting of this protein resulting in tumour reversion (Tuynder et al., 2004; Yu et al., 2006) . Some molecular mechanisms for these oncogenic effects of TCTP have been recently proposed, including its ability to protect from apoptosis through antagonizing Bax (Susini et al., 2008) and stabilizing Mcl-1 (Liu et al., 2005) . Our findings suggest that another mechanism for TCTP-associated oncogenesis may operate by activation of SK1 through stabilization and enhancement of cellular levels of eEF1A.GDP. Similarly, expression of eEF1A2 has been detected in malignant cells from other tissues, in which it has been implicated in inducing the neoplastic phenotype through undetermined means (Lee, 2003) . The guanine nucleotide-bound status of eEF1A is controlled by guanine exchange factors and guanine nucleotide dissociation inhibitors, in a manner comparable to the regulation of the small G proteins (Sprang, 1997) . Although very little is known about the comparative regulation of eEF1A1 and -2, some evidence is emerging for the existence of different protein-binding partners and regulation for each of these isoforms (Panasyuk et al., 2008; Soares et al., 2009) . Thus, it seems that the aberrant expression of eEF1A2 in malignant cells may lead to enhanced levels of eEF1A2.GDP and subsequent enhanced cellular SK1 activity and oncogenic signalling.
